<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4254">
  <stage>Registered</stage>
  <submitdate>25/10/2013</submitdate>
  <approvaldate>25/10/2013</approvaldate>
  <nctid>NCT01972841</nctid>
  <trial_identification>
    <studytitle>This is a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder</studytitle>
    <scientifictitle>A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multi-center Study to Evaluate the Efficacy, Safety and Tolerability of Combinations of Solifenacin Succinate and Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in the Treatment of Overactive Bladder</scientifictitle>
    <utrn />
    <trialacronym>SYNERGY</trialacronym>
    <secondaryid>2012-005735-91</secondaryid>
    <secondaryid>178-CL-101</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Urinary Bladder Overactive</healthcondition>
    <healthcondition>Urinary Bladder Diseases\Urologic Diseases</healthcondition>
    <healthcondition>Overactive Bladder</healthcondition>
    <healthcondition>Urgency Incontinence</healthcondition>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Other renal and urogenital disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Solifenacin succinate
Treatment: drugs - Mirabegron
Treatment: drugs - Placebo

Experimental: 1: Solifenacin 5 mg + Mirabegron 25 mg - Participants who received solifenacin 5 mg and mirabegron 25 mg once a day for 12 weeks.

Experimental: 2: Solifenacin 5 mg + Mirabegron 50 mg - Participants who received solifenacin 5 mg and mirabegron 50 mg once a day for 12 weeks.

Placebo Comparator: 3: Placebo - Participants who received matching placebo once a day for 12 weeks.

Active Comparator: 4: Solifenacin 5 mg - Participants who received solifenacin 5 mg once a day for 12 weeks.

Active Comparator: 5:Mirabegron 25 mg - Participants who received mirabegron 25 mg once a day for 12 weeks.

Active Comparator: 6: Mirabegron 50 mg - Participants who received mirabegron 50 mg once a day for 12 weeks.


Treatment: drugs: Solifenacin succinate
Oral tablet

Treatment: drugs: Mirabegron
Oral tablet

Treatment: drugs: Placebo
Oral tablet

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change from Baseline to End of Treatment (EoT) in Mean Number of Incontinence Episodes per 24 Hours - An incontinence episode is defined as the complaint of any involuntary leakage of urine. The mean number of incontinence episodes per 24 hours was calculated from data recorded by the participant per day on valid diary days during the 7-day micturition diary period.</outcome>
      <timepoint>Baseline and Week 12</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change from Baseline to EoT in Mean Number of Micturitions per 24 Hours - A micturition is defined as any voluntary micturition (excluding incontinence only episodes). The mean number of micturitions per 24 hours was calculated from data recorded by the participant per day on valid diary days during the 7-day micturition diary period.</outcome>
      <timepoint>Baseline and Week 12</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline to EoT in Mean Volume Voided per Micturition - The mean volume voided per micturition was calculated from the data recorded by the participant during 3 consecutive days with volume measurements during the 7-day micturition diary period.</outcome>
      <timepoint>Baseline and Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline to EoT in OAB Questionnaire (OAB-q) Symptom Bother Score - The OAB-q is a self-reported questionnaire with items relating to symptom bother and health-related quality of life (HRQoL). The symptom bother portion consists of 8 items, rated on a 6-point Likert scale (1 through 6). The total symptom bother score was calculated from the 8 answers and then transformed to range from 0 (least severity) to 100 (worst severity). A negative change from baseline indicates an improvement.</outcome>
      <timepoint>Baseline and Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in Subject assessment of Treatment Satisfaction-Visual Change from Baseline to EoT in Treatment Satisfaction-Visual Analogue Scale (TS-VAS) - The TS-VAS is a visual analogue scale which asks participants to rate their satisfaction with the treatment by placing a vertical mark on a line that runs from 0 (No, not at all) on the left to 10 (Yes, completely) on the right. A positive change from baseline indicates improvement.</outcome>
      <timepoint>Baseline and Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of Incontinence Episodes at Weeks 4, 8, 12 and EoT - The number of incontinence episodes is the number of times a participant records an incontinence episode during the 7-day micturition diary period prior to each visit.</outcome>
      <timepoint>Weeks 4, 8, 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline to Weeks 4, 8, 12 and EoT in Number of Incontinence Episodes</outcome>
      <timepoint>Baseline and Weeks 4, 8, 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline to Weeks 4, 8 and 12 in Mean Number of Incontinence Episodes per 24 Hours</outcome>
      <timepoint>Baseline and Weeks 4, 8, 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline to Weeks 4, 8 and 12 in Mean Number of Micturitions per 24 Hours</outcome>
      <timepoint>Baseline and Weeks 4, 8, 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline to Weeks 4, 8 and 12 in Mean Volume Voided per Micturition</outcome>
      <timepoint>Baseline and Weeks 4, 8, 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline to EoT in Corrected Micturition Frequency - Corrected micturition frequency is defined as the mean number of micturitions per 24 hours that participants had at end of treatment if their fluid intake had remained unchanged since baseline.</outcome>
      <timepoint>Baseline and Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of Urgency Incontinence Episodes at Weeks 4, 8, 12 and EOT - An urgency incontinence episode is defined as the involuntary leakage of urine accompanied by or immediately proceeded by urgency. The number of urgency incontinence episodes is number of times a participant records an urgency incontinence episode during the 7-day micturition diary period prior to each visit.</outcome>
      <timepoint>Weeks 4, 8 and 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline to Weeks 4, 8, 12 and EoT in Number of Urgency Incontinence Episodes</outcome>
      <timepoint>Baseline and Weeks 4, 8, 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline to Weeks 4, 8, 12 and EoT in Mean Number of Urgency Incontinence Episodes per 24 Hours - The mean number of urgency incontinence episodes was calculated from data recorded by the participant per day on valid diary days during the 7-day micturition diary period prior to each visit.</outcome>
      <timepoint>Baseline and Weeks 4, 8, 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline to Weeks 4, 8, 12 and EoT in Mean Number of Urgency Episodes (Grade 3 or 4) per 24 Hours - An urgency episode is a complaint of a sudden, compelling desire to pass urine, which is difficult to defer; it is recorded when a micturition or incontinence episode is recorded and the severity of urinary urgency recorded is 3 (severe urgency) or 4 (urgency incontinence) according to the Patient Perception of Intensity of Urgency Scale (PPIUS). The mean number of urgency episodes was calculated from data recorded by the participant per day on valid diary days during the 7-day micturition diary period prior to each visit.</outcome>
      <timepoint>Baseline and Weeks 4, 8, 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of Nocturia Episodes at Weeks 4, 8, 12 and EoT - A nocturia episode is defined as waking at night 1 or more times to void (i.e., any voiding associated with sleep disturbance between the time the participant goes to bed with the intention to sleep until the time the patients gets up in the morning with the intention to stay awake). The number of nocturia episodes is the number of times a participant records a nocturia episode during the 7-day micturition diary period prior to each visit.</outcome>
      <timepoint>Weeks 4, 8 and 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline to Weeks 4, 8, 12 and EoT in Number of Nocturia Episodes</outcome>
      <timepoint>Baseline and Weeks 4, 8, 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline to Weeks 4, 8, 12 and EoT in Mean Number of Nocturia Episodes per 24 Hours - The mean number of nocturia episodes was calculated from data recorded by the participant per day on valid diary days during the 7-day micturition diary period prior to each visit.</outcome>
      <timepoint>Baseline and Weeks 4, 8, 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of Pads Used at Weeks 4, 8, 12 and EoT - The number of pads used is the number of times a participant records a new pad used during the 7-day micturition diary period prior to each visit.</outcome>
      <timepoint>Weeks 4, 8 and 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline to Weeks 4, 8, 12 and EoT in Number of Pads Used</outcome>
      <timepoint>Baseline and Weeks 4, 8, 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline to Weeks 4, 8, 12 and EoT in Mean Number of Pads Used per 24 Hours - The mean number of pads used was calculated from data recorded by the participant per day on valid diary days during the 7-day micturition diary period prior to each visit.</outcome>
      <timepoint>Baseline and Weeks 4, 8, 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of Incontinence-Free Days at Weeks 4, 8, 12 and EoT - The number of incontinence-free days is the number of valid diary days during the 7-day micturition diary period with no incontinence episodes recorded.</outcome>
      <timepoint>Weeks 4, 8 and 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of Days with &lt; 8 Micturitions at Weeks 4, 8, 12 and EoT - The number of days with &lt; 8 micturitions is the number of valid diary days during the 7-day micturition diary period with less than 8 micturitions per day.</outcome>
      <timepoint>Weeks 4, 8 and 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of Incontinence-Free Days with &lt; 8 micturitions per day at Weeks 4, 8 and 12 and EoT - The number of incontinence-free days with &lt; 8 micturitions per day is the number of valid diary days during the 7-day micturition diary period with no incontinence episodes recorded and with &lt; 8 micturitions per day.</outcome>
      <timepoint>Weeks 4, 8 and 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline in Patient Perception of Bladder Condition Questionnaire (PPBC) at Weeks 4, 8 and 12 and EoT - The PPBC is a validated, global assessment tool using a 6-point Likert scale on which participants rated their subjective impression of their current bladder condition. Participants assessed their bladder condition using this scale: 1. Does not cause me any problems at all; 2. Causes me some very minor problems; 3. Causes me some minor problems; 4. Causes me (some) moderate problems; 5. Causes me severe problems; 6. Causes me many severe problems.</outcome>
      <timepoint>Baseline and Weeks 4, 8 and 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline to Weeks 4, 8 and 12 in the OAB-q Symptom Bother Score</outcome>
      <timepoint>Baseline and Weeks 4, 8 and 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline to Weeks 4, 8, 12 and EoT in Health-Related Quality of Life Questionnaire (HRQL) Total Score - The OAB-q is a self-reported questionnaire with items relating to symptom bother and health-related quality of life (HRQoL). The HRQoL portion consists of 25 HRQL items comprising 4 HRQL subscales (Coping, Concern, Sleep, and Social Interaction), scored 1-6. The total score was calculated by adding the 4 HRQoL subscale scores and transforming to a scale from 0 to 100, with higher scores indicating better quality of life. A positive change from baseline indicates an improvement.</outcome>
      <timepoint>Baseline and Weeks 4, 8 and 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline to Weeks 4, 8, 12 and EoT in HRQL Subscale Score: Coping - The OAB-q is a self-reported questionnaire with items relating to symptom bother and health-related quality of life (HRQoL). The HRQoL portion consists of 25 HRQL items comprising 4 HRQL subscales (Coping, Concern, Sleep, and Social Interaction), scored 1-6. The total score was calculated by adding the 4 HRQoL subscale scores and transforming to a scale from 0 to 100, with higher scores indicating better quality of life. A positive change from baseline indicates an improvement.</outcome>
      <timepoint>Baseline and Weeks 4, 8 and 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline to Weeks 4, 8, 12 and EoT in HRQL Subscale Score: Concern - The OAB-q is a self-reported questionnaire with items relating to symptom bother and health-related quality of life (HRQoL). The HRQoL portion consists of 25 HRQL items comprising 4 HRQL subscales (Coping, Concern, Sleep, and Social Interaction), scored 1-6. The total score was calculated by adding the 4 HRQoL subscale scores and transforming to a scale from 0 to 100, with higher scores indicating better quality of life. A positive change from baseline indicates an improvement.</outcome>
      <timepoint>Baseline and Weeks 4, 8 and 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline to Weeks 4, 8, 12 and EoT in HRQL Subscale Score: Sleep - The OAB-q is a self-reported questionnaire with items relating to symptom bother and health-related quality of life (HRQoL). The HRQoL portion consists of 25 HRQL items comprising 4 HRQL subscales (Coping, Concern, Sleep, and Social Interaction), scored 1-6. The total score was calculated by adding the 4 HRQoL subscale scores and transforming to a scale from 0 to 100, with higher scores indicating better quality of life. A positive change from baseline indicates an improvement.</outcome>
      <timepoint>Baseline and Weeks 4, 8 and 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline to Weeks 4, 8, 12 and EoT in HRQL Subscale Score: Social - The OAB-q is a self-reported questionnaire with items relating to symptom bother and health-related quality of life (HRQoL). The HRQoL portion consists of 25 HRQL items comprising 4 HRQL subscales (Coping, Concern, Sleep, and Social Interaction), scored 1-6. The total score was calculated by adding the 4 HRQoL subscale scores and transforming to a scale from 0 to 100, with higher scores indicating better quality of life. A positive change from baseline indicates an improvement.</outcome>
      <timepoint>Baseline and Weeks 4, 8 and 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Patient's Global Impression of Change (PGIC) Scale: Impression in Bladder Symptoms at Week 12 and EoT - The PGIC is a 2-part questionnaire, assessing both the change in the patient's overall condition and change in bladder condition since the start of the study (from very much worse to very much improved).</outcome>
      <timepoint>Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PGIC Scale: Impression in General Health at Week 12 and EoT - The PGIC is a 2-part questionnaire, assessing both the change in the patient's overall condition and change in bladder condition since the start of the study (from very much worse to very much improved).</outcome>
      <timepoint>Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline to EoT in European Quality of Life in 5 Dimensions (EQ-5D) Questionnaire Subscale Score: Mobility - The EQ-5D questionnaire is an international, standardized, nondisease specific instrument for describing and valuing health status, and has 5 dimensions: Mobility, Self-care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each dimension has 5 response levels ranging from level 1 (no problem or none) to level 5 (unable to perform activity).</outcome>
      <timepoint>Baseline and Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline to EoT in EQ-5D Questionnaire Subscale Score: Self-care - The EQ-5D questionnaire is an international, standardized, nondisease specific instrument for describing and valuing health status, and has 5 dimensions: Mobility, Self-care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each dimension has 5 response levels ranging from level 1 (no problem or none) to level 5 (unable to perform activity).</outcome>
      <timepoint>Baseline and Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline to EoT in EQ-5D Questionnaire Subscale Score: Usual Activities - The EQ-5D questionnaire is an international, standardized, nondisease specific instrument for describing and valuing health status, and has 5 dimensions: Mobility, Self-care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each dimension has 5 response levels ranging from level 1 (no problem or none) to level 5 (unable to perform activity).</outcome>
      <timepoint>Baseline and Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline to EoT in EQ-5D Questionnaire Subscale Score: Pain/Discomfort - The EQ-5D questionnaire is an international, standardized, nondisease specific instrument for describing and valuing health status, and has 5 dimensions: Mobility, Self-care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each dimension has 5 response levels ranging from level 1 (no problem or none) to level 5 (unable to perform activity).</outcome>
      <timepoint>Baseline and Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline to EoT in EQ-5D Questionnaire Subscale Score: Anxiety/Depression - The EQ-5D questionnaire is an international, standardized, nondisease specific instrument for describing and valuing health status, and has 5 dimensions: Mobility, Self-care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each dimension has 5 response levels ranging from level 1 (no problem or none) to level 5 (unable to perform activity).</outcome>
      <timepoint>Baseline and Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline to Week 12 and EoT in Work Productivity and Activity Impairment: Specific Health Problem Questionnaire (WPAI:SHP) Score: Percent Time Work Missed - The WPAI:SHP is a self-administered questionnaire with 6 questions (Q1=Employment status; Q2=Hours absent from work due to the bladder condition; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the bladder condition on productivity while working; Q6=Impact of the bladder condition on productivity while doing regular daily activities other than work) and a 1-week recall period. WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity, i.e., worse outcomes. A negative change from baseline indicates improvement.</outcome>
      <timepoint>Baseline and Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline to Week 12 and EoT in WPAI:SHP Score: Percent Impairment While Working - The WPAI:SHP is a self-administered questionnaire with 6 questions (Q1=Employment status; Q2=Hours absent from work due to the bladder condition; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the bladder condition on productivity while working; Q6=Impact of the bladder condition on productivity while doing regular daily activities other than work) and a 1-week recall period. WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity, i.e., worse outcomes. A negative change from baseline indicates improvement.</outcome>
      <timepoint>Baseline and Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline to Weeks 4, 8 and 12 in the TS-VAS</outcome>
      <timepoint>Baseline and Weeks 4, 8, 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants with Zero Incontinence Episodes per 24 Hours Using the Last 3 Diary Days at Weeks 4, 8, 12 and EoT - The percentage of participants with zero incontinence episodes per 24 hours postbaseline in the last 3 days prior to weeks 4, 8, 12 and EoT.</outcome>
      <timepoint>Weeks 4, 8 and 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants with = 10 Points Improvement from Baseline in the OAB-q Symptom Bother Score at Weeks 4, 8, 12 and EoT - The percentage of participants with = 10 points improvement from baseline to each visit (weeks 4, 8, 12 and EoT).</outcome>
      <timepoint>Baseline and Weeks 4, 8 and 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants with = 10 Points Improvement from Baseline in HRQL Total Score at Weeks 4, 8, 12 and EoT - The percentage of participants with = 10 points improvement from baseline to each visit (weeks 4, 8, 12 and EoT).</outcome>
      <timepoint>Baseline and Weeks 4, 8 and 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants with 50% Reduction in Mean Number of Incontinence Episodes per 24 Hours at Weeks 4, 8, 12 and EoT - The percentage of participants with = 50% decrease from baseline in mean number of incontinence episodes per 24 hours at each time point (weeks 4, 8, 12 and EoT).</outcome>
      <timepoint>Baseline and Weeks 4, 8 and 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants with Micturition Frequency Normalization at Weeks 4, 8, 12 and EoT - The percentage of participants with micturition frequency normalization is defined as any participant who had = 8 micturitions/24 hours at baseline and &lt; 8 micturitions/24 h postbaseline at weeks 4, 8, 12 and EoT.</outcome>
      <timepoint>Baseline and Weeks 4, 8 and 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants with Zero Incontinence Episodes per 24 Hours Using the Last 7 Diary Days at Weeks 4, 8, 12 and EoT - The percentage of participants with zero incontinence episodes per 24 hours postbaseline in the last 7 days prior to weeks 4, 8, 12 and EoT.</outcome>
      <timepoint>Weeks 4, 8 and 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants with = 1 Point Improvement from Baseline in PPBC at Weeks 4, 8, 12 and EoT - The percentage of participants with = 1 point improvement from baseline in PPBC at weeks 4, 8, 12 and EoT.</outcome>
      <timepoint>Baseline and Weeks 4, 8 and 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants with Major (= 2 points) Improvement from Baseline in PPBC at Weeks 4, 8, 12 and EoT - The percentage of participants with a major (= 2 points) improvement from baseline in PPBC at weeks 4, 8, 12 and EoT.</outcome>
      <timepoint>Baseline and Weeks 4, 8 and 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants Who Were Double Responders (50% Reduction in Mean Number of Incontinence Episodes per 24 Hours and at least 10 Points Improvement on OAB-q Symptom Bother Scale) at Weeks 4, 8, 12 and EoT - The percentage of participants considered as double responders, defined as participants with 50% reduction in mean number of incontinence episodes per 24 hours compared to baseline and minimal important difference reached (improvement by = 10 points) on the OAB-q Symptom Bother score at weeks 4, 8, 12 and EoT.</outcome>
      <timepoint>Baseline and Weeks 4, 8 and 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants Who Were Double Responders (50% Reduction in Mean Number of Incontinence Episodes per 24 Hours and at least 10 Points Improvement on OAB-q HRQL Total Score) at Weeks 4, 8, 12 and EoT - The percentage of participants considered as double responders, defined as participants with 50% reduction in mean number of incontinence episodes per 24 hours compared to baseline and minimal important difference reached (improvement by = 10 points) on the OAB-q HRQL total score at weeks 4, 8, 12 and EoT.</outcome>
      <timepoint>Baseline and Weeks 4, 8 and 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants Who Were Double Responders (50% Reduction in Mean Number of Incontinence Episodes per 24 Hours and at least 1 Point Improvement on PPBC) at Weeks 4, 8, 12 and EoT - The percentage of participants considered as double responders, defined as participants with 50% reduction in mean number of incontinence episodes per 24 hours compared to baseline and = 1 point improvement from baseline in PPBC at weeks 4, 8, 12 and EoT.</outcome>
      <timepoint>Baseline and Weeks 4, 8 and 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants Who Were Triple Responders (50% Reduction in Mean Number of Incontinence Episodes per 24 Hours, at least 10 Points Improvement on OAB-q Symptom Bother Scale and at least 1 Point Improvement on PPBC) at Weeks 4, 8, 12 and EoT - The percentage of participants considered as triple responders, defined as participants with 50% reduction in mean number of incontinence episodes per 24 hours compared to baseline, minimal important difference reached (improvement by = 10 points) on the OAB-q Symptom Bother score, and = 1 point improvement from baseline in PPBC at weeks 4, 8, 12 and EoT.</outcome>
      <timepoint>Baseline and Weeks 4, 8 and 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants Who Were Triple Responders (50% Reduction in Mean Number of Incontinence Episodes per 24 Hours, at least 10 Points Improvement on OAB-q HRQL Total Score and at least 1 Point Improvement on PPBC) at Weeks 4, 8, 12 and EoT - The percentage of participants considered as triple responders, defined as participants with 50% reduction in mean number of incontinence episodes per24 hours compared to baseline, minimal important difference reached (improvement by = 10 points) on the HRQL total score, and = 1 point improvement from baseline in PPBC at weeks 4, 8, 12 and EoT.</outcome>
      <timepoint>Baseline and Weeks 4, 8 and 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of Participants with Treatment-Emergent Adverse Events (TEAEs) - A TEAE refers to an adverse event (AE; defined as any untoward medical occurrence in a participant administered a study drug or who had undergone study procedures and did not necessarily have a causal relationship with this treatment) which started or worsened in the period from first double-blind medication intake until 14 days after the last double-blind medication intake. Serious TEAEs with a start date reported until 30 days after the last double-blind medication intake were also summarized as TEAEs, and also included serious TEAEs upgraded by the sponsor based on review of the sponsor's list of Always Serious terms if any upgrade was done. Drug-related TEAEs may be possible or probable, as assessed by the investigator, or records where relationship is missing.</outcome>
      <timepoint>From first dose of double-blind study drug up to 30 days after last dose of double-blind study drug (up to 16 weeks)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline to Weeks 4, 8, 12 and EoT in Postvoid Residual (PVR) Volume - PVR volume was assessed by ultrasonography or a bladder scanner.</outcome>
      <timepoint>Baseline and Weeks 4, 8 and 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline to Weeks 4, 12 and EoT in Mean 24 hours (h), Mean Daytime and Mean Nighttime Systolic Blood Pressure (SBP) - Vital signs (blood pressure and pulse rate) were monitored using an ambulatory blood pressure monitoring (ABPM) device placed on the upper arm followed by intake of the double-blind study medication and worn for at least 24 hours.</outcome>
      <timepoint>Baseline and Weeks 4 and 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline to Weeks 4, 12 and EoT in Mean 24-h, Mean Daytime and Mean Nighttime Diastolic Blood Pressure (DBP) - Vital signs (blood pressure and pulse rate) were monitored using an ambulatory blood pressure monitoring (ABPM) device placed on the upper arm followed by intake of the double-blind study medication and worn for at least 24 hours.</outcome>
      <timepoint>Baseline and Weeks 4 and 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline to Weeks 4, 12 and EoT in Mean 24-h, Mean Daytime and Mean Nighttime Pulse Rate - Vital signs (blood pressure and pulse rate) were monitored using an ambulatory blood pressure monitoring (ABPM) device placed on the upper arm followed by intake of the double-blind study medication and worn for at least 24 hours.</outcome>
      <timepoint>Baseline and Weeks 4 and 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline to Weeks 4, 12 and EoT in Mean SBP 4 to 6 Hours Postdose - Vital signs (blood pressure and pulse rate) were monitored using an ambulatory blood pressure monitoring (ABPM) device placed on the upper arm followed by intake of the double-blind study medication and worn for at least 24 hours. Tmax (time to maximum concentration) window of mirabegron and solifenacin was from 4-6 hours postdose.</outcome>
      <timepoint>Baseline and Weeks 4 and 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline to Weeks 4, 12 and EoT in Mean DBP 4 to 6 Hours Postdose - Vital signs (blood pressure and pulse rate) were monitored using an ambulatory blood pressure monitoring (ABPM) device placed on the upper arm followed by intake of the double-blind study medication and worn for at least 24 hours. Tmax (time to maximum concentration) window of mirabegron and solifenacin was from 4-6 hours postdose.</outcome>
      <timepoint>Baseline and Weeks 4 and 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline to Weeks 4, 12 and EoT in Mean Pulse Rate 4 to 6 Hours Postdose - Vital signs (blood pressure and pulse rate) were monitored using an ambulatory blood pressure monitoring (ABPM) device placed on the upper arm followed by intake of the double-blind study medication and worn for at least 24 hours. Tmax (time to maximum concentration) window of mirabegron and solifenacin was from 4-6 hours postdose.</outcome>
      <timepoint>Baseline and Weeks 4 and 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Maximum 1-hour Change from Time-matched Baseline in SBP at Weeks 4, 12 and EoT - Vital signs (blood pressure and pulse rate) were monitored using an ambulatory blood pressure monitoring (ABPM) device placed on the upper arm followed by intake of the double-blind study medication and worn for at least 24 hours.</outcome>
      <timepoint>Baseline and Weeks 4 and 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Maximum 1-hour Change from Time-matched Baseline in DBP at Weeks 4, 12 and EoT - Vital signs (blood pressure and pulse rate) were monitored using an ambulatory blood pressure monitoring (ABPM) device placed on the upper arm followed by intake of the double-blind study medication and worn for at least 24 hours.</outcome>
      <timepoint>Baseline and Weeks 4 and 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Maximum 1-hour Change from Time-matched Baseline in Pulse Rate at Weeks 4, 12 and EoT - Vital signs (blood pressure and pulse rate) were monitored using an ambulatory blood pressure monitoring (ABPM) device placed on the upper arm followed by intake of the double-blind study medication and worn for at least 24 hours.</outcome>
      <timepoint>Baseline and Weeks 4 and 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline to Weeks 4, 12 and EoT in SBP Peak/Trough Difference - Vital signs (blood pressure and pulse rate) were monitored using an ambulatory blood pressure monitoring (ABPM) device placed on the upper arm followed by intake of the double-blind study medication and worn for at least 24 hours. Peak/trough difference is defined as the difference between the highest 1-h to lowest 1-h average per participant per visit.</outcome>
      <timepoint>Baseline and Weeks 4 and 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline to Weeks 4, 12 and EoT in DBP Peak/Trough Difference - Vital signs (blood pressure and pulse rate) were monitored using an ambulatory blood pressure monitoring (ABPM) device placed on the upper arm followed by intake of the double-blind study medication and worn for at least 24 hours. Peak/trough difference is defined as the difference between the highest 1-h to lowest 1-h average per participant per visit.</outcome>
      <timepoint>Baseline and Weeks 4 and 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline to Weeks 4, 12 and EoT in Pulse Rate Peak/Trough Difference - Vital signs (blood pressure and pulse rate) were monitored using an ambulatory blood pressure monitoring (ABPM) device placed on the upper arm followed by intake of the double-blind study medication and worn for at least 24 hours. Peak/trough difference is defined as the difference between the highest 1-h to lowest 1-h average per participant per visit.</outcome>
      <timepoint>Baseline and Weeks 4 and 12</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Subject is willing and able to complete the micturition diary and questionnaires
             correctly and able to measure his/her vital signs at home at stipulated time points,
             using the device provided by the study personnel, and to adequately record the
             readings;

          -  Subject has symptoms of "wet" OAB (urinary frequency and urgency with incontinence)
             for at least 3 months;</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Subject has significant PVR volume (&gt; 150 mL);

          -  Subject has a neurological cause for detrusor overactivity (e.g. neurogenic bladder,
             diabetic neuropathy with autonomic component or bladder involvement, or systemic or
             central neurological disease such as multiple sclerosis and Parkinson's disease with
             autonomic component or bladder involvement). An autonomic component can be inferred
             when autonomic functions are affected, including heart rate, blood pressure,
             perspiration and digestion.

          -  Subject has an indwelling catheter or practices intermittent self catheterization.

          -  Subject has chronic inflammation such as bladder pain syndrome /interstitial cystitis,
             symptomatic bladder stones or any previous or current radiation cystitis.

          -  Subject has received intravesical treatment in the past 12 months with e.g., botulinum
             toxin, resiniferatoxin, capsaicin.

          -  Subject has moderate to severe hepatic impairment

          -  Subject has severe renal impairment

          -  Subject has a clinically significant abnormal ECG

          -  Subject has a concurrent malignancy or history of cancer (except noninvasive skin
             cancer) within the last 5 years prior to screening.

          -  Subject has an average QTcF interval &gt; 450 ms for males or &gt; 470 ms for females based
             on the triplicate ECGs completed at Screening or is at risk of QT prolongation (e.g.,
             family history of long QT syndrome, hypokalaemia).

          -  Subject has severe hypertension, which is defined as a sitting average systolic blood
             pressure = 180 mmHg and/or average diastolic blood pressure = 110 mmHg.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>5/11/2013</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>3527</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>22/10/2015</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Site AU61026 Ballarat Urology - Ballarat</hospital>
    <hospital>Site AU61022 Brisbane South Clinical Research Centre - Brisbane</hospital>
    <hospital>Site AU61005 Hunter Clinical Research - Broadmeadow</hospital>
    <hospital>Site AU61015 Repatriation General Hospital - Daw Park</hospital>
    <hospital>Site AU61025 Western Health - Footscray</hospital>
    <hospital>Site AU61012 Cabrini Hospital - Malvern</hospital>
    <hospital>Site AU61010 Nambour General Hospital - Nambour</hospital>
    <hospital>Site AU61002 The Royal Womens Hospital - Parkville</hospital>
    <hospital>Site AU61004 Keogh Institute for Medical Research - Perth</hospital>
    <hospital>Site AU61007 Prince of Wales Hospital - Randwick</hospital>
    <hospital>Site AU61008 Epworth Healthcare - Richmond</hospital>
    <hospital>Site AU61019 AusTrialsSherwood - Sherwood</hospital>
    <hospital>Site AU61017 Healthpac Medical Centre - Sydney</hospital>
    <hospital>Site AU61021 Royal Hospital for Women - Sydney</hospital>
    <hospital>Site AU61011 Illawarra Health and Medical Research Institute - Wollongong</hospital>
    <postcode>3350 - Ballarat</postcode>
    <postcode>4152 - Brisbane</postcode>
    <postcode>2292 - Broadmeadow</postcode>
    <postcode>5041 - Daw Park</postcode>
    <postcode>3011 - Footscray</postcode>
    <postcode>3144 - Malvern</postcode>
    <postcode>4560 - Nambour</postcode>
    <postcode>3052 - Parkville</postcode>
    <postcode>6009 - Perth</postcode>
    <postcode>2031 - Randwick</postcode>
    <postcode>3121 - Richmond</postcode>
    <postcode>4075 - Sherwood</postcode>
    <postcode>2000 - Sydney</postcode>
    <postcode>2031 - Sydney</postcode>
    <postcode>2522 - Wollongong</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Connecticut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Louisiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Montana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nebraska</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nevada</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Mexico</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oklahoma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Buenos Aires</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Ciudad Aut√≥noma Buenos Aires</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Rosario Provincia de Santa Fe</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Gent</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Roeselare</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Sint-Truiden</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Pleven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Plovdiv</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Ruse</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Sofia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Varna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Veliko Tarnovo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>New Brunswick</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Fujian</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Beijing</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Changchun</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Changsha</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Chengdu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Chongqing</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Guangzhou</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Lan Zhou</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Lanzhou</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Nanchang</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Nanjing</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Shanghai</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Suzhou</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Wenzhou</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Wuhan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Wuxi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Colombia</country>
      <state>Antioquia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Colombia</country>
      <state>Medellin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Brno</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Hradec Kralove</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Jihlava</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Novy Jicin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Olomouc</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Ostrava</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Plzen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Praha 4</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Sternberk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Uherske Hradiste</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Usti nad Labem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Aalborg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Aarhus</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Estonia</country>
      <state>Parnu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Estonia</country>
      <state>Tallinn</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Estonia</country>
      <state>Tartu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Kouvola</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Oulu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Vantaa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Colmar Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Dijon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nantes Cedex 1</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nimes Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris Cedex 20</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Pierre Benite Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Suresnes</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Tours Cedex 9</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bad Ems</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bergisch Gladbach</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bonn</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Duisburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Ganderkesee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Halle (Saale)</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Leipzig</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Lutherstadt Eisleben</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Munich</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Neustadt i. Sachsen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Rostock</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Sangerhausen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Athens</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hong Kong</country>
      <state>Hong Kong</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hong Kong</country>
      <state>Kowloon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hong Kong</country>
      <state>Shatin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Csongr√°d</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Kecskemet</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Pecs</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Sopron</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Szentes</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Veszpr√©m</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Ancona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Avellino</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Latina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milano</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Bucheon-Si</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Busan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Cheongju-si</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Daegu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Daejeon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Gwangju</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Iksan -Si</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Incheon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Jeonju-si</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seongnam-si</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Suwon-si</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Latvia</country>
      <state>Liepaja</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Latvia</country>
      <state>Olaine</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Latvia</country>
      <state>Riga</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Lithuania</country>
      <state>Kaunas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Lithuania</country>
      <state>Klaipeda</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Lithuania</country>
      <state>Vilnius</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Malaysia</country>
      <state>Georgetown</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Malaysia</country>
      <state>Kuala Lumpur</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Malaysia</country>
      <state>Kuching</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Malaysia</country>
      <state>Petaling Jaya</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Durango</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Guadalajara</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Mexico City</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Monterrey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Amsterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Enschede</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Nijmegen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Sneek</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Utrecht</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Hamilton</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Nelson</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Tauranga</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Whangarei</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Norway</country>
      <state>Hamar</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Norway</country>
      <state>Lierskogen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Norway</country>
      <state>√Ölesund</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Peru</country>
      <state>Lima</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Philippines</country>
      <state>Bacolod City</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Philippines</country>
      <state>Davao City</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Philippines</country>
      <state>Manila</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Philippines</country>
      <state>Quezon City</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Bialystok</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Chorzow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Gdynia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Lodz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Lublin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Myslowice</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Opole</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Piaseczno</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warsaw</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warszawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Wroclaw</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Brasov</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Bucuresti</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Cluj-Napoca</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Iasi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Sibiu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Timisoara</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Kazan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Penza</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Saint Petersburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>St. Petersburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Ufa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Singapore</country>
      <state>Singapore</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Bratislava</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Kosice</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Nitra</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Poprad</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Presov</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Trencin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovenia</country>
      <state>Murska Sobota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovenia</country>
      <state>Novo Mesto</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Cape Town</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Centurion</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Durban</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Meyerspark</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Paarl</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Roodepoort</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Coslada</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Esplugues de Llobregat-Barcelo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Getafe (Madrid)</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Sevilla</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Valencia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Boras</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Helsingborg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Malm√∂</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Stockholm</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Uppsala</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>V√§llingby</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taichung</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Tainan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taipei</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state>Bangkok</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state>Chiang Mai</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state>Hat Yai</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state>Khon Kaen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state>Pathum Thani</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state>Ratchathewi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Ankara</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Bursa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Denizli</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Istanbul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Chernigov</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Chernivtsi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Dnipropetrovsk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Kharkiv</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Kiev</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Kyiv</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Uzhorod</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Vinnytsya</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Zaporizhzhya</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Watfort</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Crewe</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Gillingham</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Harrow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Leeds</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Plymouth</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Reading</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Sheffield</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Astellas Pharma Europe B.V.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to examine how well two medicines (solifenacin succinate and
      mirabegron) combined work compared to each medicine alone in the treatment of bladder
      problems.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01972841</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Medical Director</name>
      <address>Astellas Pharma Europe B.V.</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>